

HEALTHCARE INNOVATIONS TO IMPROVE LIVES

INOLIFE (INOL) CORPORATE PRESENTATION
JUNE 2017





INOLIFE SNAPSHOT

A LEADER IN NEEDLE-FREE DRUG DELIVERY TECHNOLOGY

- Research, development and commercialization of needle-free injection devices for the administration of subcutaneous and intra-muscular medication
- FDA-cleared, commercially proven Inojex30™ needle-free device to market through a growing network of global distributors and directly online
- Product molds, technical know-how and IP helps protect market opportunity
- Exclusive right to purchase or license next generation needle-free powder injector
- ² • Inolife currently on the OTC Markets under ticker symbol INOL
- Inolife will soon be listed on the Canadian Securities Exchange
- Market ready for Inojex 30 needle-free injector

INJECTABLE DRUG MARKET

CURRENT USE IN CLINICAL MEDICINE

16 Billion

**INJECTIONS ANNUALLY
WORLDWIDE**

35%

**OF PRESCRIPTIONS FROM TOP
PHARMAS ARE INJECTABLE**

43%

**INCREASE IN INJECTABLE
MARKET OVER THE LAST 5 YEARS**

WHY NEEDLE-FREE?

MULTIPLE FACTORS DRIVING ADOPTION

- 17.3% of the population have either anxiety or needle phobia
- **Over 2,000** reported needlestick injuries **per day** in the US alone
 - Cost of follow-up for exposure is \$3,000 per needlestick injury, even when no infection occurs; up to \$1 million when serious infection by blood-borne pathogens
 - Cross-contamination and needle safety is a leading concern of the W.H.O.
- Used needles are considered toxic waste and the cost of disposing them is rising
- Alarming growth of the diabetes market: 422 million diabetics worldwide, ~20% of which inject themselves several times each day

A world map rendered in a watercolor style, with continents filled with various colors like blue, purple, pink, red, orange, and yellow. The map is positioned at the top of the slide.

NEEDLE-FREE MARKET

A LARGE & GROWING OPPORTUNITY

- Global market reported to be \$7.2 billion
- Growing at a rate of 14.3% annually; should reach \$10 Billion by 2019
- North American shortage of 300,000 needle-free devices in 2016
- Rest of market highly fragmented (engineering, pharma, indication specific)

TARGET MARKETS


A BROAD RANGE OF THERAPEUTIC AREAS

- ✓ **DIABETES**
- ✓ **ENDOCRINOLOGY**
- ✓ **ONCOLOGY & SUPPORTIVE CARE**
- ✓ **PAIN – ANALGESIA**
- ✓ **AUTOIMMUNE DISEASES**
- ✓ **FERTILITY HORMONES**
- ✓ **ERECTILE DYSFUNCTION**
- ✓ **VACCINES**
- ✓ **DENTAL**
- ✓ **COSMETICS**
- ✓ **BIOSIMILARS**



INOJEX30™

THE ONLY FDA “OVER-THE-COUNTER” NEEDLE-FREE INJECTION DEVICE



LIFETIME WARRANTY

INOJEX30™ STARTER KIT

MULTIPLE TOOLS FOR ALL MEDICATIONS

INJECTOR



RESET BOX



10 SYRINGES



MULTIPLE ADAPTORS



14 MM VIAL



22 MM VIAL



**PEN
ADAPTOR**



**LUER
ADAPTOR**

TRANSPORTER SET



TRANSPORTER



**TRANSPORTER
ADAPTOR**



SILITOP

COMPETITIVE LANDSCAPE

HIGHLY FRAGMENTED & INDICATION-LIMITED

PRODUCTS	COMPANY	INDICATION	TECHNOLOGY	MARKET
j-Tip	National Medicine Private company	Lidocaine	Co2, disposable	Several Countries
Dose Pro	Zogenix	Migraine	Co2, disposable	N/A
Biojector	Inovio	Vaccine (SIRNA)	Co2, reusable	USA
PharmaJet	PharmaJet Private company	Vaccine	Spring, reusable	USA
Crossjet	ZENEO	Arthritis, Allergy, Migraine	Co2, disposable	USA
SDI	Glide Pharma Private company	Diabetes, Vaccines	Spring, cartridge	Clinical phase

STOCK COMPARABLES

GOAL IS TO UPLIST TO NASDAQ BY SUMMER 2018

COMPANY	TICKER	EXCHANGE	P/S*	MARKET CAP (\$M)*
Inovio	INO	NASDAQ	15.0	565.0
Antares	ATRS	NASDAQ	7.5	389.8
CrossJect	ALCJ	PARIS	42.9	70.0
Zogenix	ZGNX	NASDAQ	14.4	322.6
Inolife	INOL	OTC Markets	1.00	69.0



OUR NEXT-GENERATION TECHNOLOGIES

FAMILY OF DISPOSABLE INJECTORS

- Inojex30™ disposable
- Inojex 50™
- Pre-filled needle-free syringe
- Nanojex needle-free powder injection

Nanojex Powder Injectors



IMPROVED EFFICACY

NANOJEX POWDER INJECTORS OFFER MULTIPLE OPPORTUNITIES

- **Thermostable** – eliminates the need for cold supplychain
- Can easily formulate and store combination formulations
- Can target specific skin layers
- Can inject pure drugs, without response delaying excipients
- Can potentially achieve direct intracellular injection: useful for DNA, RNA or protein-based drugs
- For vaccines: the epidermis is rich in antigen-presenting cells
 - Elicits both antibody and CTL responses
 - **Dose reduction** by a factor of 2.5-10 for conventional vaccines
 - **Dose reduction** by a factor of 100-1000 for DNA vaccines



OUR RESEARCH PARTNERSHIPS & COLLABORATORS

SUPPORTING PRODUCT DEVELOPMENT & BUSINESS GROWTH





Medicago is a leading clinical-stage biotechnology company that uses proprietary plant-based technologies to rapidly develop and produce novel vaccines and antibodies. Medicago is currently leading a research study using our powder injector technology in partnership with the organizations listed below.



OUR NEXT GENERATION CONTRACT MANUFACTURING PARTNER

SCALABILITY WITH SOLID QUALITY CONTROL



A company rich in tradition was founded almost 200 years ago. Röchling's Medical Division offers customers a wide range of contract manufacturing services in the field of plastics processing's and precision assemblies technologies for the Medical, Diagnostics & Pharmaceutical industry. These high quality products are used in innovative Drug Delivery Devices, Primary Packaging, Surgical Instruments and Diagnostics Disposables. Röchling Medical Division has a global footprint in Germany, USA and China



PROFESSIONAL PARTNERS

AN EXPERIENCED GROUP

INVESTMENT BANKER: MAXIM GROUP

- Full service Investment bank, dedicated to middle market and emerging growth companies
- Registered Broker-Dealer with the SEC
- Members of FINRA, SIPC, NASDAQ, and NYSE
- 363 transactions which aggregated \$33+ billion since 2013
- Market Maker in over 1,200 stocks
- \$2.8 billion of assets under management

AUDITORS: THAYER O'NEAL

- Members of the American Institute of CPA's
- Several senior staff are Certified Fraud Examiners
- Diverse firm with ability to serve clients in multiple languages

INVESTOR RELATIONS: REDCHIP COMPANIES, INC.

- Founded in 1992 and headquartered in Orlando, Florida with affiliates in New York, Pittsburg, Paris and Seoul.
- The RedChip Money Report airs on Newsmax TV and Family Channel reaching more than 100 million homes accross the USA each week.
- Our targeted retail and institutional digital media platform reaches hundreds of thousands of investors worldwide.
- Dave Gentry, CEO, is the published author of "Small Stock, Big Money"

LEGAL COUNCIL: DUNTON RAINVILLE

- Securities and Financing
- Public and private mergers and acquisitions
- Firm has over 100 lawyers

GO-TO-MARKET STRATEGY

MULTIPLE SHORT- & MID-TERM VALUE INFLECTION POINTS



Step 1: Inojex30™ reusable device with disposable to be sold direct to consumers online and through distributors - timeline: within 30 days




Step 2: Co-packing of Inojex30™ device with specific subcutaneous injectable drug - timeline: within 18 months



Step 3: Preloaded with drug of disposable needle-free syringe to be used with Inojex30™ or new Inojex disposable device - timeline: within 24 months



Step 4: Introduction of Nanojex Powder injector to specific markets segments (e.g. veterinarian) - timeline: within 24 months



Step 5: Introduction of bio-similar's in needle-free liquid syringe and powder injector - timeline: minimum of 36 month, depending on market and stage 3 testing results

SALES OBJECTIVES

PROMISSORY NOTE INTERIM FINANCING

	2017-18	2018-19	2019-20
Starter Kits	19,600	55,077	106,684
Revenue	\$12,853,233	\$41,361,563	\$108,079,510
EBITDA	\$4,334,127	\$18,926,152	\$61,297,895

INTERIM FINANCING USE OF PROCEEDS

PROMISSORY CONVERTIBLE NOTE FOR INTERIM FINANCING OF 3MM USD

Gross Offering	\$3,000,000
Less Estimated Offering Expenses and Commissions	\$200,000
Net Proceeds	\$2,800,000

PLANNED USES

Inventory	\$1,300,000
Manufacturing - phase 2 (Rochling)	\$180,000
Sales & Marketing	\$460,000
Investor Relations & Road Show	\$175,000
FDA Quality Assurance	\$120,000
Staffing and Consulting Services (general & admin)	\$185,000
Board of Directors (including meeting cost)	\$80,000
Insurance (D&O and Liability)	\$150,000
Legal & Regulatory	\$150,000
Total	\$2,800,000

FORWARD-LOOKING STATEMENTS

The presentation may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives and other forward-looking terminology such as “may,” “expects,” “believes,” “anticipates,” “intends,” “projects,” or similar terms, variations of such terms or the negative of such terms.

Forward-looking statements are based on management’s current expectations. Actual results could differ materially from those currently anticipated and such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to availability of financing, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's products and product candidates, adverse side effects or inadequate therapeutic efficacy of the Company's products that could slow or prevent product development or commercialization and the uncertainty of patent protection for the Company's intellectual property or trade secrets.



HEALTHCARE INNOVATIONS TO IMPROVE LIVES

THANK YOU